02.12.19
Brady Corporation announced that Dr. David S. Bem and Dr. Michelle E. Williams will join its Board of Directors, effective Feb. 18, 2019.
Dr. Bem is VP of science and technology and TO for PPG, a global manufacturer of paints, coatings and specialty materials. Prior to PPG, he spent eight years at Dow Chemical Company in a number of research and development roles, most recently as VP, R&D consumer solutions and infrastructure solutions, and also worked in research and development roles at Celanese Corporation and UOP/Honeywell International, Inc.
“I am impressed with Brady’s robust product pipeline and the investments made by the Company in new product development and innovation. This has been the focus of my career and I look forward to helping guide this process,” said Dr. Bem.
Dr. Williams is global group president for Altuglas International, a subsidiary of Arkema with approximately $1 billion in annual revenues. Dr. Williams leads this subsidiary, which is a global integrated leader in polymethyl methacrylate technology, which is most frequently used in acrylic glass. She joined Arkema in 2011, first as a global group president for the Oxygenes and Derivatives group before being named global group president of Altuglas in 2015. Prior to Arkema, she spent 23 years with Rohm and Haas Company and Dow Chemical in manufacturing, commercial, strategy and general management positions.
“Brady is a global leader in safety and identification solutions,” said Williams. “I’m looking forward to working with Brady’s leadership team and its Board of Directors as the company continues to focus on developing innovative solutions that solve their customers’ problems.”
“Drs. Bem’s and Williams’ expertise in the product development process and global operations will make them tremendous assets to the Brady Board of Directors,” said Conrad Goodkind, chair of Brady’s Board of Directors.
Dr. Bem is VP of science and technology and TO for PPG, a global manufacturer of paints, coatings and specialty materials. Prior to PPG, he spent eight years at Dow Chemical Company in a number of research and development roles, most recently as VP, R&D consumer solutions and infrastructure solutions, and also worked in research and development roles at Celanese Corporation and UOP/Honeywell International, Inc.
“I am impressed with Brady’s robust product pipeline and the investments made by the Company in new product development and innovation. This has been the focus of my career and I look forward to helping guide this process,” said Dr. Bem.
Dr. Williams is global group president for Altuglas International, a subsidiary of Arkema with approximately $1 billion in annual revenues. Dr. Williams leads this subsidiary, which is a global integrated leader in polymethyl methacrylate technology, which is most frequently used in acrylic glass. She joined Arkema in 2011, first as a global group president for the Oxygenes and Derivatives group before being named global group president of Altuglas in 2015. Prior to Arkema, she spent 23 years with Rohm and Haas Company and Dow Chemical in manufacturing, commercial, strategy and general management positions.
“Brady is a global leader in safety and identification solutions,” said Williams. “I’m looking forward to working with Brady’s leadership team and its Board of Directors as the company continues to focus on developing innovative solutions that solve their customers’ problems.”
“Drs. Bem’s and Williams’ expertise in the product development process and global operations will make them tremendous assets to the Brady Board of Directors,” said Conrad Goodkind, chair of Brady’s Board of Directors.
